• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高增殖活性 Ki-67 在有治愈意图的手术切除后肠胰神经内分泌肿瘤复发中起重要作用。

High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent.

机构信息

Department of Medicine 1, Division of Endocrinology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Department of Gastroenterology, Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy.

出版信息

J Neuroendocrinol. 2022 Oct;34(10):e13193. doi: 10.1111/jne.13193. Epub 2022 Aug 24.

DOI:10.1111/jne.13193
PMID:36306194
Abstract

Neuroendocrine neoplasms (NENs) present with advanced disease at diagnosis in up to 28% of cases, precluding the possibility of curative-intent surgery. Histopathological heterogeneity of this disease can be observed inter-individually as well as intra-individually during disease course. The present study aimed to assess the frequency of Ki-67 change after radical surgery, in a series of patients with radically resected entero-pancreatic neuroendocrine tumors (EP-NETs). We present the analysis of a multicenter, retrospective, series of EP-NETs G1-G2 recurring after radical resection and with histological re-evaluation at disease recurrence (DR). The primary endpoint was the description of Ki-67 change at DR compared to time of surgery. The secondary endpoint was assessment of recurrence-free survival (RFS) rates. In total, 47 patients had a second histological evaluation and could be included in the present study. Median Ki-67 at surgery was 3% (range 1-15%) but, at DR, a significant increase in the value was observed (7%, range 1-30%; p < .01) and involved 66.0% of cases, with a corresponding increase in tumor grading in 34.0% (p = .05). Median RFS of the overall population was 40 months, and was worse when Ki-67 increased at DR vs. stable Ki-67 value (36 vs. 61 months, respectively; p = .02). In conclusion, in more than half of the cases with relapse after radical surgery, a higher proliferative index with a potentially more aggressive potential was observed. Therefore, histological reassessment should be considered on DR because tailored therapeutic strategies may be required for these patients.

摘要

神经内分泌肿瘤(NENs)在诊断时,多达 28%的病例已处于晚期,排除了根治性手术的可能性。这种疾病的组织病理学异质性在个体间以及疾病过程中个体内都可以观察到。本研究旨在评估根治性手术后 Ki-67 变化的频率,在一系列接受根治性手术的肠胰神经内分泌肿瘤(EP-NETs)患者中。我们分析了一组多中心、回顾性的 EP-NETs G1-G2 患者,这些患者在根治性切除后复发,并在疾病复发(DR)时进行组织学重新评估。主要终点是比较 DR 时与手术时 Ki-67 变化的描述。次要终点是评估无复发生存率(RFS)。共有 47 名患者进行了第二次组织学评估并纳入本研究。手术时的 Ki-67 中位数为 3%(范围 1-15%),但在 DR 时,观察到明显的增加(7%,范围 1-30%;p<0.01),涉及 66.0%的病例,相应地,在 34.0%的病例中肿瘤分级增加(p=0.05)。总体人群的中位 RFS 为 40 个月,当 Ki-67 在 DR 时增加与 Ki-67 值稳定时相比更差(分别为 36 和 61 个月;p=0.02)。总之,在根治性手术后复发的病例中,超过一半的病例观察到更高的增殖指数,潜在的侵袭性更强。因此,应在 DR 时考虑进行组织学重新评估,因为这些患者可能需要量身定制的治疗策略。

相似文献

1
High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent.高增殖活性 Ki-67 在有治愈意图的手术切除后肠胰神经内分泌肿瘤复发中起重要作用。
J Neuroendocrinol. 2022 Oct;34(10):e13193. doi: 10.1111/jne.13193. Epub 2022 Aug 24.
2
Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?以根治为目的的手术:G3 神经内分泌肿瘤有手术适应证吗?
Ann Surg Oncol. 2020 May;27(5):1348-1355. doi: 10.1245/s10434-019-08049-5. Epub 2019 Nov 12.
3
Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence.肠胰神经内分泌肿瘤的根治性切除术:无复发生存率和复发风险评分的定义。
Ann Surg Oncol. 2022 Sep;29(9):5568-5577. doi: 10.1245/s10434-022-11837-1. Epub 2022 May 18.
4
Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.重新定义低级别胰腺神经内分泌肿瘤的 Ki-67 指数分层:提高其对疾病复发的预后价值。
Ann Surg Oncol. 2018 Jan;25(1):290-298. doi: 10.1245/s10434-017-6140-8. Epub 2017 Oct 27.
5
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).神经内分泌肿瘤异质性给 2010 年世界卫生组织分类带来不确定性:来自西班牙肿瘤登记处(R-GETNE)的真实世界数据。
Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12.
6
HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.HSP90 表达与胃肠胰神经内分泌肿瘤的早期复发:潜在的新型治疗靶点。
Surg Oncol. 2020 Dec;35:460-465. doi: 10.1016/j.suronc.2020.09.018. Epub 2020 Oct 7.
7
Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.胰腺神经内分泌肿瘤患者疾病进展时Ki67重新评估的影响
PLoS One. 2017 Jun 23;12(6):e0179445. doi: 10.1371/journal.pone.0179445. eCollection 2017.
8
Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.接受根治性手术的神经内分泌肿瘤患者疾病复发的预后因素。
Surg Oncol. 2016 Sep;25(3):223-8. doi: 10.1016/j.suronc.2016.05.019. Epub 2016 May 26.
9
Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.针对高度选择的IV期G3神经内分泌肿瘤的根治性意向性手术。
Am J Surg. 2020 Aug;220(2):284-289. doi: 10.1016/j.amjsurg.2020.03.009. Epub 2020 Mar 14.
10
Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.基于新分级分类法的高分化胰腺神经内分泌肿瘤根治性切除术后复发危险因素分析
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):418-25. doi: 10.1002/jhbp.47. Epub 2013 Oct 20.

引用本文的文献

1
Primary squamous cell carcinoma of the pancreas with treatment-refractory characteristics: A case report and literature review.具有治疗难治性特征的胰腺原发性鳞状细胞癌:一例报告及文献综述
J Int Med Res. 2025 Jun;53(6):3000605251345957. doi: 10.1177/03000605251345957. Epub 2025 Jun 5.
2
Small intestinal neuroendocrine tumors lack early genomic drivers, acquire DNA repair defects and harbor hallmarks of low REST expression.小肠神经内分泌肿瘤缺乏早期基因组驱动因素,存在DNA修复缺陷,并具有低REST表达的特征。
Sci Rep. 2025 May 23;15(1):17969. doi: 10.1038/s41598-025-01912-4.
3
Factors associated with grade progression in pancreatic neuroendocrine tumors.
胰腺神经内分泌肿瘤分级进展的相关因素。
Endocr Relat Cancer. 2025 Jan 30;32(3). doi: 10.1530/ERC-24-0203. Print 2025 Mar 1.
4
Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation.经治疗的G3神经内分泌肿瘤患者中转移灶的快速演变与神经内分泌癌样转化及TP53突变相关
Endocr Pathol. 2024 Dec;35(4):313-324. doi: 10.1007/s12022-024-09827-y. Epub 2024 Oct 9.
5
Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors.分级进展和患者体内肿瘤异质性作为胃肠胰神经内分泌肿瘤耐药的潜在因素
Cancers (Basel). 2023 Jul 21;15(14):3712. doi: 10.3390/cancers15143712.
6
Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms.消化神经内分泌肿瘤的时空异质性
Ther Adv Med Oncol. 2023 Jun 9;15:17588359231179310. doi: 10.1177/17588359231179310. eCollection 2023.
7
Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms.肿瘤异质性以及胃肠胰神经内分泌肿瘤管理中随之而来的实际挑战
Cancers (Basel). 2023 Mar 20;15(6):1861. doi: 10.3390/cancers15061861.